UnknownNot Applicable

Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling

60 participantsStarted 2023-08

Plain-language summary

Investigators are going to assess direct effect of SGLT2 inhibitors on left atrial remodeling in participants with nonvalvular paroxysmal atrial fibrillation regardless of diabetes status.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. with non-valvular paroxysmal atrial fibrillation (AF that terminates spontaneously or with intervention within seven days of onset).
✓. Patient age 18-60 years.
✓. Patients with Glomerular Filtration Rate (GFR) \>45 ml/min/1.73m2 (Cockcroft-Gault equation).
✓. Patient with normal left atrium or dilated (diameter \<5 cm)

Exclusion criteria

✕. Patients \< 18 yrs old.
✕. Patients with valvular heart diseases (Moderate to severe MS, severe AS, Prosthetic heart valves).
✕. Patients with left atrium \> 5cm.
✕. Patients with glomerular Filtration Rate (GFR) \<45 ml/min/1.73m2 (Cockcroft-Gault equation).
✕. Patient with ischemic heart disease (previous MI, UA, PCI or CABG).
✕. Patient with previous ischemic stroke.

What they're measuring

Left atrial remodeling

Timeframe: Before first administration of treatment and will be repeated 6 months after while still on treatment

Changes in left atrial strain

Timeframe: Before first administration of treatment and will be repeated 6 months after while still on treatment

Changes in left atrial systolic force

Timeframe: Before first administration of treatment and will be repeated 6 months after while still on treatment

Trial details

NCT IDNCT05993897

SponsorAswan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08

View on ClinicalTrials.gov More Atrial Fibrillation trials